Novartis is reported to be weighing the sale of its Ritalin, Clozaril and Exelon drugs as the Swiss giant cuts back on treatments for the central nervous system in favor of generics and other products.
The sale of the drugs, which treat attention-deficit-hyperactivity disorder, schizophrenia and Alzheimer’s disease, respectively, could command a price of more than $300 million and draw offers from other pharmaceutical companies, according to people familiar with the matter. They asked not to be identified because the deliberations are private.
